Key points are not available for this paper at this time.
Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.
Drucker et al. (Wed,) studied this question.